Use of dapivirine vaginal ring during third trimester of pre

A vaginal ring containing the antiretroviral drug dapivirine posed no safety concerns when used in the third trimester of pregnancy, according to results to date from the first study of the dapivirine ring during pregnancy and one of only a few studies of an HIV prevention product in pregnant cisgender women.

Related Keywords

Kampala , Uganda , Kenya , Malawi , Harare , Mashonaland East , Zimbabwe , Rwanda , South Africa , Zengeza , Johannesburg , Gauteng , Makerere , Katherine Bunge , Felixg Mhlanga , Emily Henderson , Johns Hopkins University , University Of Pittsburgh School Medicine , National Institute Of Allergy , Us National Institutes Of Health , Wits Reproductive Health , National Institute Of Mental Health , Shandukani Research Centre , International Partnership For Microbicides , College Of Medicine , Human Development , Institute Wits , Makerere University , World Health Organization , Johns Hopkins University Research Project In Blantyre , Microbicide Trials Network , Population Council , Research Collaboration , University Of Zimbabwe Clinical Trials Research Centre , Opportunistic Infections , Pittsburgh School , Ring Study , Discovery Industry Focus , National Institute , Infectious Diseases , Eunice Kennedy Shriver National Institute , Child Health , Mental Health , Makerere University Johns Hopkins , Zimbabwe Clinical Trials Research Centre , Lee Fairlie , International Partnership , European Medicines Agency , Dapivirine , Pregnancy , Vaginal , Kids , Allergy , Antiretroviral , Breastfeeding , Frequency , Ynecology , Shiv , Hiv Aids , Medicine , Icrobicide , Obstetrics , Pre Exposure Prophylaxis , Prophylaxis , Research , Tillbirth , Truvada ,